Compare Apartment Investment and Management Co (AIV) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Apartment Investment and Management Co vs State Street SPDR S&P Biotech ETF — how do they compare? Apartment Investment and Management Co trades at $2.62 (market cap $376.16M), while State Street SPDR S&P Biotech ETF trades at $158.83. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Apartment Investment and Management Co nearer its low. Which is the better fit depends on your goals.
| AIV | XBI | |
|---|---|---|
Market Cap | $376.16M | — |
Sector | Real Estate | Broad Market / Factor |
52-Week High | $7.93 | $164.28 |
52-Week Low | $2.59 | $86.92 |
Enterprise Value | $738.32M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AIV trades at $2.605, down 0.57% today, with a bearish technical signal from moving averages. The company reported mixed quarterly earnings, beating in Q1 and Q4 2025 but missing in Q2 and Q3. Despite a net income margin of 400.05% in 2025, revenue declined to $138.49M from $209M in 2024. Analyst consensus shows 1 Buy and 2 Hold ratings, indicating cautious optimism. A dividend of $1.30 is scheduled for H1-2026.
Outlook: AIV's high profitability metrics and undervalued P/B ratio of 0.76 present potential upside, but declining revenue and bearish technicals pose risks. Investment opportunity lies in dividend yield and earnings recovery, while key risks include revenue volatility and competitive pressures in real estate.
XBI trades at $158.81, up 0.49% today, with a bullish technical signal supported by moving averages. The ETF shows strong momentum with a 17% monthly gain and 75% annual return, driven by biotech sector strength. Analyst coverage is limited to one hold rating, while recent news highlights institutional buying interest and positive sector developments including M&A activity and drug trial successes.
The outlook remains positive given biotech's breakout from multi-year bear markets, though elevated volatility and policy risks persist. Key opportunities include AI-driven drug discovery and sustained M&A momentum, while risks involve sector-specific volatility and regulatory uncertainty. The ETF's equal-weight approach provides diversified exposure to biotech innovation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Apartment Investment and Management Co
Apartment Investment & Management Co is a self-managed real estate investment trust. It is focused on property development, redevelopment and various other value-creating investment strategies, targeting the U.S multifamily market. Its operating segments are Development and Redevelopment
Read more on AIV →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
